Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(1)
Other(1)

Detailed Status

Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

withdrawn150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
unknownnot_applicable

Exposures to Perinatal Adverse Experiences: Multimodal Omics Signature of Stress Vulnerability and Resilience and Preventive Strategies

NCT05951738
withdrawn

Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Residences

NCT04932837

Clinical Trials (2)

Showing 2 of 2 trials
NCT05951738Not Applicable

Exposures to Perinatal Adverse Experiences: Multimodal Omics Signature of Stress Vulnerability and Resilience and Preventive Strategies

Unknown
NCT04932837

Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Residences

Withdrawn

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2